Tem­pest Ther­a­peu­tics’ triple com­bo shows promise in first-line liv­er can­cer, stock jumps

Tem­pest Ther­a­peu­tics said Fri­day morn­ing that its ex­per­i­men­tal liv­er can­cer ther­a­py on top of stan­dard-of-care treat­ments helped shrink tu­mors in more pa­tients com­pared to stan­dard-of-care alone.

In an ear­ly cut of da­ta from a Phase I/II tri­al, 7 of 40 pa­tients (17.5%) with he­pa­to­cel­lu­lar car­ci­no­ma who were treat­ed with Tem­pest’s TPST-1120 on top of Tecen­triq and Avastin as a first op­tion had con­firmed re­spons­es com­pared with 3 of 29 (10.3%) who re­ceived on­ly Tecen­triq and Avastin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER